Jinsong Geng1, Haini Bao2,3, Zhe Feng2, Jingyi Meng2, Xiaolan Yu2, Hao Yu4. 1. Medical School of Nantong University, 226001, Nantong, Jiangsu, China. gjs@ntu.edu.cn. 2. Medical School of Nantong University, 226001, Nantong, Jiangsu, China. 3. The First People's Hospital of Lianyungang, 222061, Lianyungang, Jiangsu, China. 4. Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, 02215, Boston, MA, USA.
Abstract
BACKGROUND: Diabetes is a major public health concern with a considerable impact on healthcare expenditures. Deciding on health insurance coverage for new drugs that meet patient needs is a challenge facing policymakers. Our study aimed to assess patients' preferences for public health insurance coverage of new anti-diabetic drugs in China. METHODS: We identified six attributes of new anti-diabetic drugs and used the Bayesian-efficient design to generate choice sets for a discrete choice experiment (DCE). The DCE was conducted in consecutive samples of type 2 diabetes patients in Jiangsu Province. The mixed logit regression model was applied to estimate patient-reported preferences for each attribute. The interaction model was used to investigate preference heterogeneity. RESULTS: Data from 639 patients were available for analysis. On average, the most valued attribute was the improvement in health-related quality of life (HRQoL) (β = 1.383, p < 0.001), followed by positive effects on extending life years (β = 0.787, p < 0.001), and well-controlled glycated haemoglobin (β = 0.724, p < 0.001). The out-of-pocket cost was a negative predictor of their preferences (β = -0.138, p < 0.001). Elderly patients showed stronger preferences for drugs with a lower incidence of serious side effects (p < 0.01) and less out-of-pocket costs (p < 0.01). Patients with diabetes complications favored more in the length of extended life (p < 0.01), improvement in HRQoL (p < 0.05), and less out-of-pocket costs (p < 0.001). CONCLUSION: The new anti-diabetic drugs with significant clinical effectiveness and long-term health benefits should become the priority for public health insurance. The findings also highlight the value of accounting for preference heterogeneity in insurance policy-making.
BACKGROUND: Diabetes is a major public health concern with a considerable impact on healthcare expenditures. Deciding on health insurance coverage for new drugs that meet patient needs is a challenge facing policymakers. Our study aimed to assess patients' preferences for public health insurance coverage of new anti-diabetic drugs in China. METHODS: We identified six attributes of new anti-diabetic drugs and used the Bayesian-efficient design to generate choice sets for a discrete choice experiment (DCE). The DCE was conducted in consecutive samples of type 2 diabetes patients in Jiangsu Province. The mixed logit regression model was applied to estimate patient-reported preferences for each attribute. The interaction model was used to investigate preference heterogeneity. RESULTS: Data from 639 patients were available for analysis. On average, the most valued attribute was the improvement in health-related quality of life (HRQoL) (β = 1.383, p < 0.001), followed by positive effects on extending life years (β = 0.787, p < 0.001), and well-controlled glycated haemoglobin (β = 0.724, p < 0.001). The out-of-pocket cost was a negative predictor of their preferences (β = -0.138, p < 0.001). Elderly patients showed stronger preferences for drugs with a lower incidence of serious side effects (p < 0.01) and less out-of-pocket costs (p < 0.01). Patients with diabetes complications favored more in the length of extended life (p < 0.01), improvement in HRQoL (p < 0.05), and less out-of-pocket costs (p < 0.001). CONCLUSION: The new anti-diabetic drugs with significant clinical effectiveness and long-term health benefits should become the priority for public health insurance. The findings also highlight the value of accounting for preference heterogeneity in insurance policy-making.
Authors: Margaret E Kruk; Jennifer C Johnson; Mawuli Gyakobo; Peter Agyei-Baffour; Kwesi Asabir; S Rani Kotha; Janet Kwansah; Emmanuel Nakua; Rachel C Snow; Mawuli Dzodzomenyo Journal: Bull World Health Organ Date: 2010-05 Impact factor: 9.408
Authors: Kevin Marsh; J Jaime Caro; Erica Zaiser; James Heywood; Alaa Hamed Journal: Int J Technol Assess Health Care Date: 2017-12-26 Impact factor: 2.188
Authors: David C Wheeler; June James; Dipesh Patel; Adie Viljoen; Amar Ali; Marc Evans; Kevin Fernando; Debbie Hicks; Nicola Milne; Philip Newland-Jones; John Wilding Journal: Diabetes Ther Date: 2020-09-29 Impact factor: 2.945